2025 Asia-Pacific Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report
Description
The 2025 Asia-Pacific Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asia-Pacific AI in Drug Discovery market include Atomwise Inc., BenevolentAI, Exscientia, and Insilico Medicine. Atomwise, known for its AtomNet platform using deep learning for structure-based drug design, is expanding its collaborations in Asia for novel small molecule discoveries. BenevolentAI leverages AI to accelerate drug development through strategic partnerships with pharmaceutical firms in the region. Exscientia collaborates with global leaders like Takeda and AWS to utilize AI and machine learning for end-to-end drug discovery automation, prominently in Japan. Insilico Medicine has secured FDA investigational new drug approvals and significant funding, partnering with Jiangsu Hengrui Pharmaceuticals in China to advance AI-driven molecular design.
These companies are driving growth across key Asia-Pacific markets—China, Japan, South Korea, and India—supported by increasing investments, advanced R&D, and government initiatives to boost AI adoption in drug discovery. China leads with substantial venture capital inflows and over 100 AI pharma firms focused on cutting-edge AI technologies. Japan's pharmaceutical industry benefits from partnerships integrating proprietary AI platforms into discovery workflows. South Korea and India also contribute with multiple drug candidates in various clinical stages, emphasizing oncology and neurodegenerative diseases. This vibrant ecosystem facilitates faster, cost-efficient drug discovery, fostering innovations that address unmet medical needs in the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asia-Pacific AI in Drug Discovery market include Atomwise Inc., BenevolentAI, Exscientia, and Insilico Medicine. Atomwise, known for its AtomNet platform using deep learning for structure-based drug design, is expanding its collaborations in Asia for novel small molecule discoveries. BenevolentAI leverages AI to accelerate drug development through strategic partnerships with pharmaceutical firms in the region. Exscientia collaborates with global leaders like Takeda and AWS to utilize AI and machine learning for end-to-end drug discovery automation, prominently in Japan. Insilico Medicine has secured FDA investigational new drug approvals and significant funding, partnering with Jiangsu Hengrui Pharmaceuticals in China to advance AI-driven molecular design.
These companies are driving growth across key Asia-Pacific markets—China, Japan, South Korea, and India—supported by increasing investments, advanced R&D, and government initiatives to boost AI adoption in drug discovery. China leads with substantial venture capital inflows and over 100 AI pharma firms focused on cutting-edge AI technologies. Japan's pharmaceutical industry benefits from partnerships integrating proprietary AI platforms into discovery workflows. South Korea and India also contribute with multiple drug candidates in various clinical stages, emphasizing oncology and neurodegenerative diseases. This vibrant ecosystem facilitates faster, cost-efficient drug discovery, fostering innovations that address unmet medical needs in the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
